For the year ending 2025-12-31, RARE had $252M increase in cash & cash equivalents over the period. -$472M in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -575 |
| Stock-based compensation | 153 |
| Amortization of discount on marketable securities, net | 4 |
| Depreciation and amortization | 35 |
| Non-cash royalty revenue | 112 |
| Non-cash interest expense on liabilities for sales of future royalties | 62 |
| Other | 2 |
| Accounts receivable | 31 |
| Inventory | 6 |
| Prepaid expenses and other assets | 10 |
| Accounts payable, accrued, and other liabilities | 24 |
| Net cash used in operating activities | -466 |
| Purchase of property, plant, and equipment | 6 |
| Purchase of marketable securities | 186 |
| Proceeds from sale of marketable securities | 0 |
| Proceeds from maturities of marketable securities | 444 |
| Payments for intangible asset | 15 |
| Other | 1 |
| Net cash provided by (used in) investing activities | 236 |
| Proceeds from the sale of future royalties, net | 392 |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net | 0 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | 80 |
| Proceeds from the issuance of common stock under equity plans, net | 6 |
| Proceeds from issuance of equity from noncontrolling interest | 0 |
| Other | 0 |
| Net cash provided by financing activities | 478 |
| Effect of exchange rate changes on cash | 4 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 252 |
| Cash and cash equivalents at beginning of period | 184 |
| Cash and cash equivalents at end of period | 436 |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)